Published in J Virol on June 01, 2004
Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol (2007) 4.40
Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol (2005) 2.94
Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) (2010) 2.48
Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med (2013) 2.02
Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest (2008) 1.62
Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol (2005) 1.60
Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med (2008) 1.54
Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology (2007) 1.35
Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology (2008) 1.31
The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog (2013) 1.23
Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. J Virol (2008) 1.21
Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion. J Immunol (2009) 1.19
The level of viral antigen presented by hepatocytes influences CD8 T-cell function. J Virol (2007) 1.16
Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog (2014) 1.16
A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One (2008) 1.14
Hepatitis B infection: current concepts and future challenges. QJM (2012) 1.08
The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol Immunol (2014) 1.05
T-cell responses in hepatitis B and C virus infection: similarities and differences. Emerg Microbes Infect (2013) 1.00
Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases. J Virol (2010) 1.00
Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol (2009) 0.99
Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses. Cell Mol Immunol (2014) 0.97
Immune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virus-infected children on combined therapy. J Virol (2010) 0.93
Therapeutic vaccines in HBV: lessons from HCV. Med Microbiol Immunol (2015) 0.93
Cellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy. Virol J (2011) 0.92
Activated IL-23/IL-17 pathway closely correlates with increased Foxp3 expression in livers of chronic hepatitis B patients. BMC Immunol (2011) 0.92
Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate. J Clin Immunol (2011) 0.91
Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. J Clin Invest (2013) 0.91
The role of natural killer cells and CD8(+) T cells in hepatitis B virus infection. Front Immunol (2014) 0.91
Associations between HLA class I alleles and escape mutations in the hepatitis B virus core gene in New Zealand-resident Tongans. J Virol (2010) 0.90
Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection. PLoS One (2011) 0.90
Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels. PLoS One (2013) 0.88
Age-Dependent Immune Events during HBV Infection from Birth to Adulthood: An Alternative Interpretation. Front Immunol (2014) 0.88
Variability and conservation in hepatitis B virus core protein. BMC Microbiol (2005) 0.88
Viral hepatitis B: clinical and epidemiological characteristics. Cold Spring Harb Perspect Med (2014) 0.88
Regulation of T cell proliferation by JMJD6 and PDGF-BB during chronic hepatitis B infection. Sci Rep (2014) 0.88
Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control. World J Gastroenterol (2015) 0.87
Dissecting the dendritic cell controversy in chronic hepatitis B virus infection. Cell Mol Immunol (2014) 0.87
Hepatitis B virus splice-generated protein induces T-cell responses in HLA-transgenic mice and hepatitis B virus-infected patients. J Virol (2007) 0.87
Hepatitis B virus large surface protein: function and fame. Hepatobiliary Surg Nutr (2015) 0.86
Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues. Mol Ther (2013) 0.85
HBV-Specific Adaptive Immunity. Viruses (2009) 0.85
Regulation of T cell function by microRNA-720. Sci Rep (2015) 0.84
Dynamic analysis of CD127 expression on memory CD8 T cells from patients with chronic hepatitis B during telbivudine treatment. Virol J (2010) 0.84
Hepatitis B virus DNA is more powerful than HBeAg in predicting peripheral T-lymphocyte subpopulations in chronic HBV-infected individuals with normal liver function tests. World J Gastroenterol (2008) 0.84
Natural history of chronic hepatitis B virus infection. Med Microbiol Immunol (2014) 0.84
Decreased peripheral natural killer cells activity in the immune activated stage of chronic hepatitis B. PLoS One (2014) 0.83
Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination. J Immunol (2016) 0.82
Effect of dipterinyl calcium pentahydrate on hepatitis B virus replication in transgenic mice. J Transl Med (2010) 0.82
TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut (2014) 0.82
Hepatitis B: future curative strategies. Curr Opin Infect Dis (2014) 0.81
Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B. World J Gastroenterol (2014) 0.81
Clinical significance of chronic hepatitis B virus infection in patients with primary Sjögren's syndrome. Clin Rheumatol (2011) 0.81
T lymphocytes from chronic HCV-infected patients are primed for activation-induced apoptosis and express unique pro-apoptotic gene signature. PLoS One (2013) 0.81
Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response? Med Microbiol Immunol (2014) 0.81
The Role of Immune Cells in Chronic HBV Infection. J Clin Transl Hepatol (2015) 0.80
Interleukin-21 gene polymorphisms and chronic hepatitis B infection in a Chinese population. World J Gastroenterol (2015) 0.80
Serum levels of B-cell activating factor in chronic hepatitis B virus infection: association with clinical diseases. J Interferon Cytokine Res (2014) 0.80
Natural course of chronic hepatitis B is characterized by changing patterns of programmed death type-1 of CD8-positive T cells. World J Gastroenterol (2010) 0.80
Interleukin-21 responses in patients with chronic hepatitis B. J Interferon Cytokine Res (2014) 0.79
Design of therapeutic vaccines: hepatitis B as an example. Microb Biotechnol (2011) 0.79
Natural Killer p46 Controls Hepatitis B Virus Replication and Modulates Liver Inflammation. PLoS One (2015) 0.79
Functional aspects of intrahepatic hepatitis B virus-specific T cells induced by therapeutic DNA vaccination. Mol Ther (2014) 0.79
HLA-A is a Predictor of Hepatitis B e Antigen Status in HIV-Positive African Adults. J Infect Dis (2015) 0.78
B and T lymphocyte attenuator is highly expressed on intrahepatic T cells during chronic HBV infection and regulates their function. J Gastroenterol (2013) 0.78
Infected hematopoietic stem cells and with integrated HBV DNA generate defective T cells in chronic HBV infection patients. J Viral Hepat (2014) 0.78
Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications. Future Virol (2012) 0.78
Hepatitis B virus genome replication triggers toll-like receptor 3-dependent interferon responses in the absence of hepatitis B surface antigen. Sci Rep (2016) 0.78
Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load. World J Gastroenterol (2009) 0.78
A mouse model for studying the clearance of hepatitis B virus in vivo using a luciferase reporter. PLoS One (2013) 0.77
Efficacy of pre-S-containing HBV vaccine combined with lamivudine in the treatment of chronic HBV infection. Dig Dis Sci (2008) 0.77
Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end? Med Microbiol Immunol (2014) 0.77
Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck. Hepat Res Treat (2010) 0.77
Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection. J Clin Invest (2017) 0.76
Resistance to lamivudine therapy: is there more than meets the eye? Gut (2005) 0.75
Influence of Treg cells and HBV genotype on sustained response and drug resistance in the treatment with nucleoside drugs. Braz J Med Biol Res (2017) 0.75
Study of human B7 homolog 1 expression in patients with hepatitis B virus infection. World J Gastroenterol (2012) 0.75
Innate immune targets of hepatitis B virus infection. World J Hepatol (2016) 0.75
Towards the elimination and eradication of hepatitis B. J Virus Erad (2015) 0.75
Emerging drugs for hepatitis B. Expert Opin Emerg Drugs (2007) 0.75
Frequency-dependent selection drives HBeAg seroconversion in chronic hepatitis B virus infection. Evol Med Public Health (2013) 0.75
Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection. Iran J Basic Med Sci (2016) 0.75
T-bet expression in CD8+ T cells associated with chronic hepatitis B virus infection. Virol J (2016) 0.75
Dynamic Perturbations of CD4 and CD8 T Cell Receptor Repertoires in Chronic Hepatitis B Patients upon Oral Antiviral Therapy. Front Immunol (2017) 0.75
Cytotoxic T lymphocytes and CD4 epitope mutations in the pre-core/core region of hepatitis B virus in chronic hepatitis B carriers in Northeast Iran. Indian J Gastroenterol (2017) 0.75
Interferon-α-induced CD100 on naïve CD8(+) T cells enhances antiviral responses to hepatitis C infection through CD72 signal transduction. J Int Med Res (2017) 0.75
The impact of KIR-HLA genotype on hepatitis B virus clearance in Iranian infected individuals. Med Microbiol Immunol (2017) 0.75
Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. Front Immunol (2017) 0.75
Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A (1987) 8.11
Chronic hepatitis B. Hepatology (2001) 5.90
Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology (2001) 4.81
Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology (1994) 4.77
CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol (2003) 4.42
The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 3.78
Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature (1995) 3.61
HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol (1993) 3.42
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 3.34
Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol (1990) 3.31
Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity (2000) 2.94
Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med (1991) 2.88
Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology (1999) 2.62
Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol (1996) 2.47
Cytotoxic T cells and viral hepatitis. J Clin Invest (1997) 2.46
Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology (2000) 2.45
T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nat Immunol (2002) 2.21
Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J Clin Invest (1992) 2.20
Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med (1994) 2.18
Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest (1996) 2.04
Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol (2002) 2.03
Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology (2001) 1.99
Anergy and exhaustion are independent mechanisms of peripheral T cell tolerance. J Exp Med (1995) 1.86
Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. J Immunol (1999) 1.86
Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med (1996) 1.78
Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol (1991) 1.76
Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med (2002) 1.66
Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest (1997) 1.62
Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology (1997) 1.58
Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J Virol (2002) 1.56
The serology of chronic hepatitis B infection revisited. J Clin Invest (1993) 1.54
Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. J Clin Invest (1997) 1.50
Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology (2002) 1.41
Proliferative response of CD4+ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e-minus hepatitis B virus mutants. Hepatology (1995) 1.32
The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication. J Hepatol (2002) 1.30
Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A*2402, the most common HLA class I allele in East Asia. J Hepatol (2001) 1.29
Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Virology (1999) 1.08
Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma. Hepatology (1999) 0.98
A longitudinal analysis of cytotoxic T lymphocyte precursor frequencies to the hepatitis B virus in chronically infected patients. J Viral Hepat (2001) 0.93
Tracking the source of the hepatitis B virus-specific CD8 T cells during lamivudine treatment. J Infect Dis (2003) 0.90
HLA-A2 1 restricted peptides from the HBx antigen induce specific CTL responses in vitro and in vivo. Vaccine (2002) 0.89
Translation of immunological knowledge into better treatments of chronic hepatitis B. J Hepatol (2003) 0.86
RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03
The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res (2007) 9.32
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med (2011) 6.85
Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J (2010) 5.43
Increase in viral gastroenteritis outbreaks in Europe and epidemic spread of new norovirus variant. Lancet (2004) 5.25
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13
The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle (2008) 4.95
Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol (2007) 4.40
Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS (2007) 4.40
Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol (2009) 4.39
Surgical treatment of permanent diaphragm paralysis after interscalene nerve block for shoulder surgery. Anesthesiology (2013) 4.25
Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis (2008) 3.84
Spreading of RNA targeting and DNA methylation in RNA silencing requires transcription of the target gene and a putative RNA-dependent RNA polymerase. Plant Cell (2002) 3.73
Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity (2012) 3.58
Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res (2010) 3.21
An RNA-dependent RNA polymerase prevents meristem invasion by potato virus X and is required for the activity but not the production of a systemic silencing signal. Plant Physiol (2005) 3.14
An optimized isolation and labeling platform for accurate microRNA expression profiling. RNA (2005) 3.12
TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A (2004) 3.04
Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis (2006) 3.04
Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania. AIDS (2002) 2.93
Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther (2009) 2.92
High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology (2004) 2.91
Viral gastroenteritis outbreaks in Europe, 1995-2000. Emerg Infect Dis (2003) 2.79
Interventions for supporting informal caregivers of patients in the terminal phase of a disease. Cochrane Database Syst Rev (2011) 2.76
Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther (2011) 2.75
Dementia in the acute hospital: prospective cohort study of prevalence and mortality. Br J Psychiatry (2009) 2.75
The promise of microRNA replacement therapy. Cancer Res (2010) 2.68
Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut (2010) 2.66
Sufficiently important difference: expanding the framework of clinical significance. Med Decis Making (2005) 2.65
Hunting for consensus: reconciling bushmeat harvest, conservation, and development policy in West and Central Africa. Conserv Biol (2007) 2.50
Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol (2003) 2.50
Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol (2004) 2.48
Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med (2007) 2.32
Validity of the alcohol use disorders identification test in college students. Alcohol Clin Exp Res (2004) 2.30
Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. J Clin Microbiol (2008) 2.24
International collaborative study to compare reverse transcriptase PCR assays for detection and genotyping of noroviruses. J Clin Microbiol (2003) 2.23
Diagnostic reverse-transcription polymerase chain reaction kit for filoviruses based on the strain collections of all European biosafety level 4 laboratories. J Infect Dis (2007) 2.22
A randomized, controlled trial of an aerosolized vaccine against measles. N Engl J Med (2015) 2.16
A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med (2013) 2.11
Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology (2009) 2.10
Diagnosing norovirus-associated infectious intestinal disease using viral load. BMC Infect Dis (2009) 2.09
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
Paracetamol: are therapeutic doses entirely safe? Lancet (2006) 2.07
Proinflammogenic effects of low-toxicity and metal nanoparticles in vivo and in vitro: highlighting the role of particle surface area and surface reactivity. Inhal Toxicol (2007) 2.06
Global distribution of measles genotypes and measles molecular epidemiology. J Infect Dis (2011) 2.03
Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother (2007) 2.02
The pulmonary toxicology of ultrafine particles. J Aerosol Med (2002) 2.02
Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology (2012) 1.94
Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology (2009) 1.94
Enteral tube feeding for older people with advanced dementia. Cochrane Database Syst Rev (2009) 1.90
Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology (2009) 1.88
Mumps outbreaks across England and Wales in 2004: observational study. BMJ (2005) 1.87
Community incidence of norovirus-associated infectious intestinal disease in England: improved estimates using viral load for norovirus diagnosis. Am J Epidemiol (2010) 1.86
Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. J Hepatol (2013) 1.83
Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res (2007) 1.83
Personalized exposure assessment: promising approaches for human environmental health research. Environ Health Perspect (2005) 1.83
Expansins and cell growth. Curr Opin Plant Biol (2003) 1.83
Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. Emerg Infect Dis (2007) 1.79
Early identification of common-source foodborne virus outbreaks in Europe. Emerg Infect Dis (2003) 1.75
Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol (2003) 1.73
Dendrodendritic inhibition and simulated odor responses in a detailed olfactory bulb network model. J Neurophysiol (2003) 1.72
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72
Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev (2009) 1.70
Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology (2009) 1.70
A two-compartment mathematical model of endotoxin-induced inflammatory and physiologic alterations in swine. Crit Care Med (2012) 1.69
Heterologous T cell immunity in severe hepatitis C virus infection. J Exp Med (2005) 1.68
IL-1β production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog (2013) 1.67
'Nipped in the Budd': hepatic venous outflow obstruction in evolution. Eur J Gastroenterol Hepatol (2005) 1.66
Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med (2002) 1.66
Phenoxodiol--an isoflavone analog--induces apoptosis in chemoresistant ovarian cancer cells. Oncogene (2003) 1.65
Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol (2003) 1.64
Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest (2008) 1.62
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology (2011) 1.62
Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol (2005) 1.60
Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol (2011) 1.60
Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis. Hepatology (2003) 1.59
Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology (2003) 1.59
Diagnosing rotavirus A associated IID: Using ELISA to identify a cut-off for real time RT-PCR. J Clin Virol (2009) 1.59
The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology (2002) 1.57
Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex system in human cirrhosis. J Hepatol (2002) 1.57
IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J Immunol (2013) 1.57
Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol (2003) 1.55
Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res (2012) 1.55
Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med (2008) 1.54
Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog (2010) 1.51
Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl (2004) 1.50
Effect of albumin dialysis on intracranial pressure increase in pigs with acute liver failure: a randomized study. Crit Care Med (2006) 1.50
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol (2011) 1.49
Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology (2011) 1.49